EXEL
Price
$22.12
Change
+$0.20 (+0.91%)
Updated
May 2, 6:59 PM EST
89 days until earnings call
INCY
Price
$53.24
Change
+$0.15 (+0.28%)
Updated
May 3, 9:20 AM EST
88 days until earnings call
Ad is loading...

EXEL vs INCY ᐉ Comparison: Which is Better to Invest?

Header iconEXEL vs INCY Comparison
Open Charts EXEL vs INCYBanner chart's image
Exelixis
Price$22.12
Change+$0.20 (+0.91%)
Volume$1.84M
CapitalizationN/A
Incyte
Price$53.24
Change+$0.15 (+0.28%)
Volume$200
CapitalizationN/A
View a ticker or compare two or three
EXEL vs INCY Comparison Chart

Loading...

EXELDaily Signal changed days agoGain/Loss if shorted
 
Show more...
INCYDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
EXEL vs. INCY commentary
May 03, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXEL is a StrongSell and INCY is a Buy.

COMPARISON
Comparison
May 03, 2024
Stock price -- (EXEL: $22.12 vs. INCY: $53.09)
Brand notoriety: EXEL and INCY are both notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EXEL: 137% vs. INCY: 107%
Market capitalization -- EXEL: $6.44B vs. INCY: $11.92B
EXEL [@Biotechnology] is valued at $6.44B. INCY’s [@Biotechnology] market capitalization is $11.92B. The market cap for tickers in the [@Biotechnology] industry ranges from $559.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.61B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EXEL’s FA Score shows that 0 FA rating(s) are green whileINCY’s FA Score has 0 green FA rating(s).

  • EXEL’s FA Score: 0 green, 5 red.
  • INCY’s FA Score: 0 green, 5 red.
According to our system of comparison, INCY is a better buy in the long-term than EXEL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EXEL’s TA Score shows that 2 TA indicator(s) are bullish while INCY’s TA Score has 6 bullish TA indicator(s).

  • EXEL’s TA Score: 2 bullish, 7 bearish.
  • INCY’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, INCY is a better buy in the short-term than EXEL.

Price Growth

EXEL (@Biotechnology) experienced а -5.99% price change this week, while INCY (@Biotechnology) price change was +3.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.31%. For the same industry, the average monthly price growth was -0.53%, and the average quarterly price growth was +1244.27%.

Reported Earning Dates

EXEL is expected to report earnings on Jul 31, 2024.

INCY is expected to report earnings on Jul 30, 2024.

Industries' Descriptions

@Biotechnology (+5.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for EXEL with price predictions.
OPEN
A.I.dvisor published
a Summary for INCY with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
INCY($11.9B) has a higher market cap than EXEL($6.44B). EXEL has higher P/E ratio than INCY: EXEL (34.03) vs INCY (16.09). EXEL YTD gains are higher at: -7.795 vs. INCY (-15.448).
EXELINCYEXEL / INCY
Capitalization6.44B11.9B54%
EBITDAN/AN/A-
Gain YTD-7.795-15.44850%
P/E Ratio34.0316.09212%
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
EXEL vs INCY: Fundamental Ratings
EXEL
INCY
OUTLOOK RATING
1..100
145
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
64
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
7564
PRICE GROWTH RATING
1..100
5462
P/E GROWTH RATING
1..100
5496
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INCY's Valuation (64) in the Biotechnology industry is in the same range as EXEL (76). This means that INCY’s stock grew similarly to EXEL’s over the last 12 months.

INCY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as EXEL (100). This means that INCY’s stock grew similarly to EXEL’s over the last 12 months.

INCY's SMR Rating (64) in the Biotechnology industry is in the same range as EXEL (75). This means that INCY’s stock grew similarly to EXEL’s over the last 12 months.

EXEL's Price Growth Rating (54) in the Biotechnology industry is in the same range as INCY (62). This means that EXEL’s stock grew similarly to INCY’s over the last 12 months.

EXEL's P/E Growth Rating (54) in the Biotechnology industry is somewhat better than the same rating for INCY (96). This means that EXEL’s stock grew somewhat faster than INCY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EXELINCY
RSI
ODDS (%)
Bearish Trend 4 days ago
65%
Bullish Trend 1 day ago
46%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
65%
Bullish Trend 1 day ago
56%
Momentum
ODDS (%)
Bearish Trend 1 day ago
72%
Bullish Trend 1 day ago
59%
MACD
ODDS (%)
Bearish Trend 1 day ago
71%
Bullish Trend 1 day ago
58%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
69%
Bullish Trend 1 day ago
61%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
63%
Bearish Trend 1 day ago
65%
Advances
ODDS (%)
Bullish Trend 5 days ago
65%
Bullish Trend 1 day ago
60%
Declines
ODDS (%)
Bearish Trend 3 days ago
69%
Bearish Trend 11 days ago
67%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
64%
Aroon
ODDS (%)
Bearish Trend 1 day ago
60%
Bearish Trend 1 day ago
64%
View a ticker or compare two or three
Ad is loading...
EXELDaily Signal changed days agoGain/Loss if shorted
 
Show more...
INCYDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
DOT.X7.2851160.402072
+5.84%
Polkadot cryptocurrency
COTI.X0.1132090.003306
+3.01%
COTI cryptocurrency
SUPER.X0.9132570.021807
+2.45%
SuperVerse cryptocurrency
MBL.X0.0043290.000092
+2.17%
MovieBloc cryptocurrency
YFII.X478.1352005.543884
+1.17%
DFI.Money cryptocurrency

EXEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, EXEL has been loosely correlated with SRPT. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if EXEL jumps, then SRPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXEL
1D Price
Change %
EXEL100%
+0.89%
SRPT - EXEL
36%
Loosely correlated
-0.21%
ALNY - EXEL
34%
Loosely correlated
+0.23%
TECH - EXEL
33%
Poorly correlated
+2.91%
RVMD - EXEL
32%
Poorly correlated
+0.95%
MRSN - EXEL
32%
Poorly correlated
-0.30%
More

INCY and

Correlation & Price change

A.I.dvisor indicates that over the last year, INCY has been loosely correlated with EXEL. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if INCY jumps, then EXEL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INCY
1D Price
Change %
INCY100%
+0.28%
EXEL - INCY
45%
Loosely correlated
+0.89%
JAZZ - INCY
40%
Loosely correlated
-0.92%
AXON - INCY
39%
Loosely correlated
+1.66%
TVTX - INCY
38%
Loosely correlated
+2.67%
UTHR - INCY
37%
Loosely correlated
+1.17%
More